Development of the 21-gene assay and its application in clinical practice and clinical trials.
about
Breast cancer in the personal genomics eraBCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedProgress in adjuvant chemotherapy for breast cancer: an overviewThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisFourth Generation of Next-Generation Sequencing Technologies: Promise and ConsequencesExpanding the understanding of biases in development of clinical-grade molecular signatures: a case study in acute respiratory viral infectionsProspective Validation of a 21-Gene Expression Assay in Breast CancerClinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival modelMass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancerFactors influencing the statistical power of complex data analysis protocols for molecular signature development from microarray dataA kernel-based integration of genome-wide data for clinical decision support.A prognostic gene expression signature in infratentorial ependymoma.Systematic functional perturbations uncover a prognostic genetic network driving human breast cancerGeneSigDB--a curated database of gene expression signatures.Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmOptimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome.Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.A fuzzy gene expression-based computational approach improves breast cancer prognosticationPrognostic cancer gene signatures share common regulatory motifsGene expression-based prognostic signatures in lung cancer: ready for clinical use?Biological subtypes of breast cancer: Prognostic and therapeutic implications.Tailoring to RB: tumour suppressor status and therapeutic response.Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component.Predictive biomarker validation in practice: lessons from real trials.Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.A multigene predictor of outcome in glioblastoma.Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology ProgramNode-Negative Breast Cancer: Which Patients Should Be Treated?A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling.Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypesEngaging in health behaviors to lower risk for breast cancer recurrenceTranscriptional shift identifies a set of genes driving breast cancer chemoresistance
P2860
Q24602679-D57B4840-EF98-49D5-A096-67B2EDE9030DQ24610409-930E4344-9983-4E66-9E44-49AF79F407CDQ26798078-ADF323ED-C4ED-4E3B-AF9A-E3D4385A1978Q26861418-2DBD4D69-5190-4A8E-8437-D60B6385E7ECQ28068789-0495BD0F-C968-40DA-8035-B76C9B491D43Q28744065-BFB44D83-5858-4DCC-9C61-19CD13799076Q29011698-9FA66407-BC11-43E0-A855-9C542D3A5BCEQ29248640-EB51C876-4539-47A6-8CD9-65C770522C70Q30401624-57F800E5-25A3-4158-94B3-45A9A343400DQ30423830-445A5C60-C2A0-4B36-8371-8F969CA7A1B7Q31098350-BEEC2651-BC99-4E38-937E-74578884BF00Q31130084-CA36B9A3-9FF8-4626-9883-B424751FF7DEQ33418596-E0A91D1C-1DF4-4868-9C0A-7654C596E9EAQ33428301-05D3CC82-57BD-45CC-B8F8-A9B8075EA516Q33581494-C54AD3E0-3EF0-4E29-846E-2F24D79C6F3CQ33591245-7C3C05FA-6088-4E5A-8354-4CE2F5A537CAQ33600628-152825FC-1B0F-4D78-B94A-721A3CDE353EQ33654352-3802EBBC-7A62-463F-BBCB-0CE9B0DB4B97Q33692020-9135E61A-EA06-4BCA-9E55-3C06FD5C8373Q33731278-556F0EBA-49CE-4B74-B97B-CD500FB8E9AEQ33756398-506EFF69-208C-48E5-A354-1C91EE6D29E0Q33761298-DAFC6345-FC5A-434F-B309-2E5C3F227009Q33765404-D93CE243-063A-45A8-94E5-C1C622B15501Q33766513-BC4B50E6-E449-4336-8B8E-B5AC54EADF75Q33775506-EBB6F0EA-97B1-4509-910D-22E184B9ADE7Q33861620-4027AECD-6C7F-4996-A5DA-8AF2ECF9AB52Q33881338-729AEAEB-2CF3-4086-8416-110AC2DD6415Q33988433-93F690F9-59CD-4FBD-803C-3A0B469C04D8Q34023695-80827030-DB5B-4FBA-9751-E47BF34170FCQ34040108-7E49DDC6-082A-48D5-8398-7A010514F5EEQ34044904-B6AF0212-F752-42B1-AEB0-E950376E903FQ34110168-A8C4F9B1-68B6-42FD-B827-D8645C7B97C0Q34128373-0C925FAC-5196-43BC-9E62-2D483AD4D923Q34132666-57A7107F-447A-4FDC-9F16-9EE5877F54A4Q34155601-94912185-1D38-402F-8543-E51964CD6409Q34284270-2C9E08A4-19DE-4484-8FF9-73ECD32AE744Q34334455-DF56F761-AB77-4E97-AEC1-D810306BFABEQ34385677-450AA6C0-BE36-444F-B54B-60BEF6211527Q34551573-B75A9CA7-C84D-4267-B8A5-7FAF858DEA3CQ34552025-7B22CFF8-D0C8-4CAD-A32F-6758517C03E1
P2860
Development of the 21-gene assay and its application in clinical practice and clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of the 21-gene ass ...... practice and clinical trials.
@en
Development of the 21-gene ass ...... practice and clinical trials.
@nl
type
label
Development of the 21-gene ass ...... practice and clinical trials.
@en
Development of the 21-gene ass ...... practice and clinical trials.
@nl
prefLabel
Development of the 21-gene ass ...... practice and clinical trials.
@en
Development of the 21-gene ass ...... practice and clinical trials.
@nl
P356
P1476
Development of the 21-gene ass ...... practice and clinical trials.
@en
P2093
Joseph A Sparano
Soonmyung Paik
P304
P356
10.1200/JCO.2007.15.1068
P407
P577
2008-02-01T00:00:00Z